Obese patients who took the new weight loss drug Qsymia were more than 70 percent less likely to develop type 2 diabetes compared to patients who were taking a placebo, according to a late-stage clinical trial. Type 2 diabetes is a chronic condition in which the body does not produce any or enough insulin, causing unstable blood sugar levels. Being overweight significantly increases the risk of developing the disease. Qsymia was approved last year and became the first weight loss pill to be approved for sale in the United States in 13 years. The drug is intended for people with a ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.